PCOS Risk Assessment Method Using Combined Hormonal and Cycle Data

The patent combines multiple diagnostic parameters (menstrual cycle data, androgen levels, AMH levels, ultrasound findings) into a single integrated risk score. This merging of multiple tests into one composite indicator simplifies the diagnostic process while maintaining comprehensive assessment, directly resolving the contradiction between diagnostic accuracy and process complexity.

The patent transforms qualitative clinical assessments and multiple quantitative measurements into a standardized numerical risk score with defined thresholds. This parameter transformation enables objective risk stratification (low, medium, high risk) without requiring complex interpretation of individual test results, reducing the expertise burden while preserving diagnostic precision.

The patent introduces a computational risk assessment model as an intermediary between raw diagnostic data and clinical decision-making. This mediator automatically processes multiple parameters and generates an objective risk score, eliminating the need for subjective expert interpretation of ultrasound images and other test results, thereby improving ease of operation while maintaining precision.

The patent replaces the mechanical/subjective process of expert ultrasound interpretation with an automated computational system. The risk assessment algorithm objectively combines data from multiple sources including ultrasound measurements, hormonal levels, and menstrual history, substituting human expert analysis with a standardized computational approach that is easier to implement and less prone to variability.